A new targeted biologic for the estimated 19,000 Australian adults living with severe chronic plaque psoriasis1 will be listed on the Pharmaceutical Benefits Scheme (PBS) on February 1, 2019 for those who meet the reimbursement criteria. ILUMYA™ (tildrakizumab) belongs to a new class of biologic medicines, known as interleukin (IL) inhibitors, that specifically block a…
The Liberal National Government will make two new medicines for the treatment of the skin condition psoriasis more affordable, saving patients up to $32,600 per year. The medicine Tremfya® (Guselkumab) is being listed on the Pharmaceutical Benefits Scheme (PBS) from February 1 for the treatment of severe chronic plaque psoriasis. The medicine would cost around…
January 27, 2019
Deepti Sharma is the Director of a childcare centre, she has held this position for last 5 years.
Deepti has been living with psoriasis for past 32 years. “All my life I could never wear short dresses or sleeveless tops. I am always self-conscious about how my skin is looking.
I have been supported all along by my amazing husband, my 11 years old daughter and my 2 year old son.
I joined psoriasis Australia to help people like me, and to spread the knowledge of advancement in the treatment of Psoriasis and Psoriatic Arthritis.